EQS-News: Marinomed Biotech AG: Changes to the Management Board

EQS-News: Marinomed Biotech AG / Key word(s): Personnel
Marinomed Biotech AG: Changes to the Management Board

31.01.2025 / 12:10 CET/CEST
The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════

 Marinomed Biotech AG: Changes to the Management Board

• CFO Pascal Schmidt is resigning at the end of January 2025
• Gabriele Ram, former Wienerberger AG, takes over the management of the
finance department on an interim basis
• Restructuring proceedings successfully completed, financing of the
Company secured by the sale of the Carragelose business unit

Korneuburg, Austria, 31. January 2025 – Marinomed Biotech AG (VSE:MARI)
announces that CFO Pascal Schmidt is leaving the Company as of January
31^st, 2025. Gabriele Ram will be taking over the administration of the
financial agendas on an interim basis. Mrs. Ram brings extensive financial
experience to Marinomed. In the past 10 years, she has held several
C-Level positions in various companies in Germany and Austria. Until
recently, she served as CFO for Wienerberger Piping Solutions, a former
business unit of the stock-listed Wienerberger AG.

“We would like to thank Pascal for his many years of commitment to
Marinomed. We have experienced some exciting times together, starting with
the IPO in 2019. Recently, the challenges we faced were quite demanding,
but we were able to overcome them also thanks to his help. We wish him all
the best and are pleased to welcome Gabriele Ram, an experienced financial
expert, to our team”, Andreas Grassauer, CEO of Marinomed, says. “With the
restructuring proceedings officially ended, we are now back in control and
are focusing on the future. Most importantly, we are handing over the
Carragelose business to Unither Pharmaceuticals, which paves the way for
fully dedicating ourselves to the commercialization of the Marinosolv
technology platform.”

Simon Nebel, Chairman of Supervisory Board, comments: “In the name of the
Supervisory Board of Marinomed I thank Pascal for his valuable work. We
wish him all the best and much success for his future endeavors.”

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The
Company develops innovative patent-protected products in the therapeutic
areas immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of Carragelose®. The Marinosolv® technology
improves the solubility and bioavailability of hardly soluble compounds
and is used to develop new therapeutics for autoreactive immune disorders.
The virology segment includes Carragelose®-based over-the-counter (OTC)
products to prevent and treat respiratory viral infections that are
partnered in more than 40 countries. The Company is headquartered in
Korneuburg, Austria, and is listed on the Vienna Stock Exchange
(VSE:MARI). For further information, please visit:
[1] https://www.marinomed.com.

For further inquiries contact:

Marinomed Biotech AG
PR & IR: Lucia Ziegler
T: +43 2262 90300 158
E-Mail: [2]pr@marinomed.com 
E-Mail: [3]ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.

 

══════════════════════════════════════════════════════════════════════════

31.01.2025 CET/CEST This Corporate News was distributed by EQS Group.
www.eqs.com

══════════════════════════════════════════════════════════════════════════

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2079095

 
End of News EQS News Service

2079095  31.01.2025 CET/CEST

References

Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2079095&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. pr@marinomed.com
3. ir@marinomed.com

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender